Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Public ClinicalTrials.gov record NCT00357500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.
Study identification
- NCT ID
- NCT00357500
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Interventions
- celecoxib Drug
- cyclophosphamide Drug
- etoposide Drug
- fenofibrate Drug
- thalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2004
- Primary completion
- Jan 31, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Sep 30, 2014
2005 – 2013
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Connecticut Children's Medical Center | Hartford | Connecticut | 06106 | — |
| Miami Children's Hospital | Miami | Florida | 33155-4069 | — |
| Children's Memorial Hospital - Chicago | Chicago | Illinois | 60614 | — |
| Maine Medical Center Research Institute | Scarborough | Maine | 04074-7205 | — |
| Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis | Minnesota | 55404 | — |
| St. Louis Children's Hospital | St Louis | Missouri | 63110 | — |
| Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
| NYU Cancer Institute at New York University Medical Center | New York | New York | 10016 | — |
| Hasbro Children's Hospital | Providence | Rhode Island | 02903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Leukemia trials
Other public records listing Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07227584: ALL Backbone in AYAs Recruiting
- NCT04898790: Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant Recruiting
- NCT06152809: CIML NK Cells With Venetoclax for AML Recruiting
- NCT06053268: Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors Active, not recruiting
- NCT07714044: Rutgers University Study of the Genetics of Blood Cancers Not yet recruiting
- NCT06469307: Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00357500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2014 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00357500 live on ClinicalTrials.gov.